Robert W Baird News

The firm set an "outperform" rating on the stock. A number of other firms have also recently commented on ONXX.

Baird Venture Partners, a unit of Milwaukee-based Robert W. Baird & Co., has joined with the State of Wisconsin Investment Board to lead a $6.2 million investment into Zurex Pharma, a Madison biotechnology firm developing products aimed at preventing infections, in the biotech's first major funding round.

MRC Global : William Blair initiated coverage of this company with a rating of Outperform .

's stock had its "neutral" rating restated by analysts at Robert W. Baird in a research report issued to clients and investors on Tuesday.

The firm set a "neutral" rating on the stock. Separately, analysts at Robert W. Baird initiated coverage on shares of MRC Global in a research note to investors on Tuesday.

Editor's Note: Robert W. Baird & Co. issued a client newsletter to investors following the March towable sales report from Statistical Surveys Inc.

CC Industries Inc., the Chicago-based private equity arm of the family that is led by Bill Crown, will invest along with CC Industries-owned truck-maker Great Dane and Baird's Asian private equity unit.

Editor's Note: Robert W. Baird & Co. issued a client newsletter to investors following the March motorhome sales report from Statistical Surveys Inc.

The firm currently has a $6.00 target price on the stock. Gentiva Health Services traded up 1.40% on Tuesday, hitting $7.22. Gentiva Health Services has a 1-year low of $2.81 and a 1-year high of $28.21. The company's market cap is $219.7 million.

Other equities research analysts have also recently issued reports about the stock.

Wall St. Watchdog reveals information about companies for which stock analysts either upgraded or downgraded the shares on May 15th.

NEW YORK &#8212 Shares of Gentiva Health Services Inc. jumped Tuesday after a Robert W. Baird & Co.

's stock had its "neutral" rating reiterated by equities research analysts at Robert W. Baird in a research note issued to investors on Tuesday.

Other equities research analysts have also recently issued reports about the stock.

The firm currently has a "buy" rating and a $13.00 price target on the company's shares.

Of the shares in the offering, 5,572,703 shares are being offered by Ignite, and 196,528 shares are being offered by selling shareholders.

's stock had its "outperform" rating reiterated by investment analysts at Robert W. Baird in a note issued to investors on Thursday.

They currently have a $17.00 price target on the stock, down from their previous price target of $21.00. Separately, analysts at Jefferies Group reiterated an "underperform" rating on shares of AMAG Pharmaceuticals in a research note to investors on Tuesday, March 6th.

Separately, analysts at Robert W. Baird cut their price target on shares of ECA Marcellus Trust from $17.00 to $15.00 in a research note to investors on Tuesday, March 13rd.

Separately, analysts at Robert W. Baird initiated coverage on shares of Jive Software in a research note to investors on Tuesday, February 28th.